GPC (glycerophosphocholine)

Glycerophosphocholine (GPC / Alpha-GPC): A Comprehensive Reference

1. Identity, Chemistry, and Natural Sources

Names and Chemical Identity

L-α-Glycerophosphorylcholine (alpha-GPC, choline alfoscerate, sn-glycero-3-phosphocholine) is a natural choline compound found in the brain. The production of phospholipids starts with specific fatty acids from glycerophosphocholine (GPC; glycero-3-phosphocholine; α-GPC or choline alfoscerate; l-α-glyceryl phosphorylcholine). These multiple names all refer to the same molecule. The compound belongs to the glycerophospholipid family and is formally classified as a phosphodiester.

Glycerophosphocholine (GPC) is a small phosphodiester made up of a choline molecule attached to a phosphate group, which is in turn attached to a glycerol molecule. Phosphatidylcholine (PtdC) is a large phospholipid made up of two fatty acids attached to glycerophosphocholine, underscoring GPC's structural relationship to the broader class of membrane phospholipids. GPC is a typical metabolite of phosphatidylcholine (PC), but they differ significantly in their structures.

Natural Occurrence

L-alpha-glycerylphosphorylcholine (L-α-GPC), commonly referred to as glycerophosphorylcholine (GPC) or choline alfoscerate, is a choline-containing compound widely found in nature. Glycerophosphocholine (GPC) also known as Alpha-Glycerophosphocholine is a substance derived from lecithin of vegetable sources. It is a multifunctional nutrient present in all mammalian cells. GPC occurs in substantial concentration in breast milk, underscoring its high nutritional value. It is also present in cow's, goat's and ewe's milk and in the dairy products thereof, and in small amounts also in lecithins of different plants, such as corn, soybean. It is a naturally occurring choline compound found in the brain and in small amounts in foods such as milk and organ meats.

Endogenous Biosynthesis

Since glycerophosphocholine (GPC) was first identified in the 1950s, several synthesis pathways have been reported for different tissues: liver (Kennedy and Weiss 1956), canine kidney (Nakanishi and Burg 1989), renal medulla (Beck et al. 1990) and other cell types. Its synthesis is complex and to date at least three phospholipases have been proposed as catalysts for GPC synthesis in kidney. Gallazzini et al. found that neuropathy target esterase (NTE), also identified as phospholipase B, catalyzes GPC synthesis in response to high NaCl concentrations. Another GPC synthesis pathway involves sequential activity of a phospholipase A and a lysophospholipase. Glycero-3-phosphocholine (GPC), the product of the complete deacylation of phosphatidylcholine (PC), was long thought to not be a substrate for reacylation.

Commercial Preparation

Industrially, alpha-GPC is produced by the chemical or enzymatic deacylation of phosphatidylcholine-enriched soya phospholipids followed by chromatographic purification. Alpha-GPC may also be derived in small amounts from highly purified soy lecithin as well as from purified sunflower lecithin. The novel food subject of European regulatory applications is L-alpha-GPC produced by chemical means starting from phosphatidylcholine (PC)-enriched soya lecithin and is available in two forms: a viscous liquid GPC 85% and a powder Alpha Size 100P. It is not a phospholipid, but a phospholipid-derived substance due to its lack of lipophilic fatty acids.

2. Historical and Traditional Use

GPC does not have a documented history of use as an isolated traditional medicinal or dietary preparation in any classical herbal medicine system (e.g., Ayurveda, Traditional Chinese Medicine, or European herbalism), since it was not identified as a discrete chemical entity until the mid-twentieth century. Its clinical history, therefore, begins within the framework of modern pharmacology and neurology.

Early research in Europe focused on its neuroprotective properties, building on the understanding of choline's role in neuronal function. During the late 1980s and early 1990s, initial clinical trials in Italy and other European countries demonstrated promising results for Alpha-GPC in improving cognitive recovery following ischemic attacks and in managing symptoms of senile dementia. These findings contributed to its approval as a prescription drug in Italy for treating cognitive decline associated with neurodegenerative diseases, marking a key milestone in its medical application.

In the 1990s, Alpha-GPC began transitioning toward broader availability as an over-the-counter nootropic supplement outside of prescription contexts, particularly in the United States. It is a non-prescription drug in most countries. L-alpha-GPC (or choline alfoscerate) is the main constituent of Gliatilin® (or Delecit®), a medicinal product authorised at the national level in some EU and non-EU countries, that primarily acts on the central nervous system and is used to treat cognitive, memory, and attentional disorders in elderly patients. In Europe, it is sold in Italy and Poland as capsules or as a solution for injection at the maximum dose of 1000 mg.

Despite its 1985 marketing authorization, there are still discrepancies between countries regarding its approval as a prescription medicine and discussions about its effectiveness.

3. Key Constituents, Active Compounds, and Mechanisms of Action

Choline Delivery to the Brain

Alpha-GPC is a parasympathomimetic acetylcholine precursor which has been investigated for its potential for the treatment of Alzheimer's disease and other dementias. Alpha-GPC rapidly delivers choline to the brain across the blood–brain barrier and is a biosynthetic precursor of acetylcholine. After oral consumption, GPC is rapidly absorbed because of its high hydrophilicity. It is a biosynthetic intermediate in phospholipid metabolism, especially the formation of phosphatidylcholine, a major component of neuronal membranes.

Cholinergic Neurotransmission

Choline is a precursor to acetylcholine (ACh), a diverse neurotransmitter in areas including the hippocampus, cerebral cortex, and neuromuscular junction, where it functions in a crucial role for memory formation, cognitive function, and muscle activation through the transfer of action potentials between neurons and muscle fibers. After oral ingestion, GPC is converted metabolically to phosphatidylcholine, the active form of choline that is able to increase acetylcholine levels in the brain.

Additional Neurochemical Mechanisms

As well as facilitating cholinergic neurotransmission, evidence also indicates GPC can promote γ-aminobutyric acid (GABA) release, enhance protein kinase C activity, facilitate hippocampal neurogenesis, upregulate neurotrophic factors, and inhibit inflammation. Additionally, GPC has beneficial effects on such conditions as ischemic/hypoxic conditions, ionizing radiation-induced damage, exercise performance, growth hormone release, and liver damage.

Intestinal Metabolism

Glycerophosphocholine (GPC) is an intracellular metabolite in phosphatidylcholine metabolism and has been studied for endogenous choline supply in cells. Caco-2 cell monolayer experiments showed that exogenously added GPC was hydrolyzed to choline in the apical medium, and the resulting choline was transported into the Caco-2 cells and further to the basolateral medium. Glycerophosphodiesterase 1 (Gpcpd1/GDE5) hydrolyzes GPC to choline in vitro and is widely expressed in the gastrointestinal epithelium.

Growth Hormone and Ergogenic Effects

The potential mechanism by which A-GPC could confer enhanced strength and power performance involves increased bioavailable choline, which may result in augmented acetylcholine synthesis in neurons. A-GPC has been shown to augment acetylcholine levels in CNS neurons. A-GPC has also been shown to increase growth hormone secretion through the action of acetylcholine-stimulated catecholamine release.

Membrane Structure

Choline is a critical component of the neuronal phospholipid bilayer and an important nutrient for the human body involved in the function of numerous organs like the liver, kidney, spleen, and lungs. By serving as a precursor for phosphatidylcholine biosynthesis, GPC directly supports the structural integrity of cell membranes throughout the body.

4. Scientific Evidence by Area of Use

4.1 Cognitive Decline, Alzheimer's Disease, and Dementia

This is the area with the largest and most clinically relevant body of evidence for alpha-GPC. Choline alphoscerate and citicoline are clinically tested cholinergic precursors that have demonstrated efficacy, safety, and tolerability in patients with dementia and other neurological conditions.

A landmark multicenter, double-blind, randomized, placebo-controlled trial (De Jesus Moreno Moreno, 2003) investigated GPC at 1,200 mg/day in patients with mild-to-moderate Alzheimer's dementia and reported significant cognitive improvement. Moreno (2003) published data on cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate.

A more recent randomized, double-blind, placebo-controlled trial examined GPC in amnestic mild cognitive impairment (MCI). In this multicenter, randomized, placebo-controlled trial, 100 study subjects with mild cognitive impairment underwent a double-blind SHCog™ soft capsule (600 mg αGPC) or placebo treatment for 12 weeks. The primary efficacy outcome included changes from baseline on the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog). After 12 weeks of αGPC treatment, the ADAS-cog score decreased by 2.34 points, which was significantly greater than the change observed in the placebo group. No serious adverse events were reported, and no study subjects discontinued the intervention because of AEs.

The ASCOMALVA trial is among the most significant controlled studies of alpha-GPC in Alzheimer's disease with comorbid cerebrovascular disease. The ASCOMALVA trial involved 113 patients with mild to moderate AD. In patients in the reference treatment group (donepezil + placebo), a slight time-dependent worsening of MMSE and ADAS-cog scores was found. In the active treatment group, the administration of donepezil + α-GPC countered the decline of MMSE and ADAS-cog scores. The effect of the association on psychometric tests was statistically significant after 12 months of treatment. The combination of donepezil plus α-GPC was more effective than donepezil alone in countering symptoms of apathy in AD.

A 2023 systematic review and meta-analysis examined the pooled evidence. α-GPC alone or in combination with donepezil improved cognition, behavior, and functional outcomes among patients with neurological conditions associated with cerebrovascular injury. Choline alphoscerate (alpha glyceryl phosphorylcholine, α-GPC) is a choline-containing phospholipid used as a medicine or nutraceutical to improve cognitive function impairment occurring in neurological conditions including adult-onset dementia disorders.

A 2025 systematic review and meta-analysis published in Frontiers in Neurology comparing alpha-GPC to citicoline concluded: The findings provide valuable insights into the effectiveness of alpha-GPC as a treatment for cognitive impairment in individuals with dementia disorders of Alzheimer's type. The observed improvement in cognitive function suggests that alpha-GPC may offer a safe and promising alternative or adjunct to existing therapeutic interventions. This finding suggests that trials should conduct longer-term RCTs in this area. Alpha-GPC provides greater and more sustained cognitive benefits than citicoline, supporting its potential role as a more effective therapeutic option for dementia and cognitive dysfunction, including early-stage cognitive decline.

Evidence strength: Moderate to moderately strong for use in Alzheimer's disease and MCI, particularly in combination with acetylcholinesterase inhibitors. The only double-blind multicenter trial of α-GPC reported that active treatment using donepezil and α-GPC might slow progressive cognitive decline compared with donepezil treatment alone among 113 participants with Alzheimer disease with cerebrovascular injury after a 12- and 24-month observation period. Apart from this trial, there have been few well-designed studies with large sample sizes to confirm the efficacy of α-GPC. Longer-term, larger RCTs are needed.

4.2 Stroke Recovery and Cerebrovascular Disease

The clinical efficacy and tolerability of alpha-glycerophosphocholine (alpha-GPC) were tested in a clinical open multicenter trial on 2044 patients suffering from recent stroke or transient ischemic attacks. Alpha-GPC was administered after the attack at the daily dose of 1000 mg intramuscularly for 28 days and orally at the dose of 400 mg three times daily during the following 5 months. The Mathew Scale mean increased 15.9 points in 28 days in a statistically significant way (p < 0.001). At the end of the 5-month oral administration, the Crichton Rating Scale mean significantly decreased 4.3 points (p < 0.001); the MMST mean significantly increased (p < 0.001), reaching the "normality" score at the 3rd month assessment. The GDS score at the end of the trial corresponded to "no cognitive decline" or "forgetfulness" in 71% of the patients.

A systematic review and meta-analysis found that α-GPC, either alone or combined with donepezil, improved cognitive, behavioral, and functional outcomes in patients with neurological conditions associated with cerebrovascular injury. When given immediately following a stroke or ischemia attack, alpha-GPC appears to be neuroprotective. Due to the human trials starting treatment with intramuscular injections and then following up with oral maintenance, it is not certain how doing solely oral therapy works.

Evidence strength: The large Italian multicenter trial (n=2,044) was open-label and uncontrolled, limiting certainty. However, it remains a significant observational data set. Combined with controlled trials using add-on therapy, evidence for a beneficial role in post-stroke cognitive recovery is promising but requires replication in randomized controlled designs.

4.3 Cognition in Healthy Adults and Acute Effects

Supplementation with alpha-glycerylphosphorylcholine (A-GPC) can maintain choline levels, but its ability to offer support towards cognition in healthy adults remains an area of ongoing research. Using a randomized, double-blind, placebo-controlled, crossover approach, 20 resistance-trained males consumed either a placebo, 630 mg A-GPC, or 315 mg A-GPC. After resting hemodynamic assessments, participants took their assigned dose and had cognitive assessments (Stroop, N-Back, and Flanker), visual analog scales, and hemodynamics evaluated 60 minutes after ingestion.

A double-blind, placebo-controlled crossover study measuring mood, cognitive function, power, speed, and agility dosed participants as follows: Twenty participants consumed 200 mg of Alpha-GPC, 400 mg of Alpha-GPC, 200 mg of caffeine, and a placebo in a randomized, double-blind, placebo-controlled, crossover design. Participants performed measurements 30 minutes after supplementation: visual analog scales for six different moods, a serial subtraction test, and tests for reaction time, hand-eye coordination, power, speed, and agility. Serial subtraction test scores were 18.1% and 10.5% faster in the low-dose Alpha-GPC group compared to caffeine and placebo, respectively.

Evidence strength: Preliminary. Studies in healthy young adults are small, often acute (single-dose), and inconsistently positive. The weight of evidence for cognitive enhancement in non-impaired populations is weaker than for clinical populations with cognitive decline.

4.4 Motivation and Mood

A single-blind, randomized, placebo-controlled study investigated GPC on motivation. Participants were administered capsules containing either 200 mg of αGPC or cellulose (placebo). They self-administered two capsules, once daily at bedtime for 2 weeks, for a total daily dose of 400 mg αGPC in the treatment group. These findings suggest that αGPC supplementation has an increased effect on motivation of healthy subjects.

Choline alphoscerate (α-GPC), a cholinergic drug, is indicated in the treatment of pseudodepression in the elderly, a condition that corresponds to the actual definition of subthreshold depression. A review highlights the role of α-GPC in the treatment of subthreshold depression in older subjects.

Evidence strength: Preliminary. Single studies with small samples; replication in larger RCTs is required.

4.5 Athletic Performance, Power Output, and Growth Hormone

Several human studies have investigated alpha-GPC in the context of physical performance. A foundational pilot study using a randomized, placebo-controlled, crossover design examined the acute effects of a single dose: Seven men with at least two years of resistance training experience ingested 600 mg A-GPC (as AlphaSize™) or a placebo 90 minutes prior to completing 6 sets × 10 repetitions of Smith Machine squats at 70% of their pre-determined 1-repetition maximum. Peak GH increased 44-fold during A-GPC (from 0.19 ± 0.06 to 8.4 ± 2.1 ng/mL) vs. 2.6-fold during placebo (p < 0.03). Peak bench press force was 14% greater in A-GPC (933 ± 89 N) vs. placebo (818 ± 77 N, p < 0.02). Trends toward higher peak bench press power (P < 0.13) and lower post-exercise RER (P < 0.12) were noted in the A-GPC trial. A-GPC had no statistically significant effect on peak power, rate of force development, RMR, or cardiovascular hemodynamics.

A double-blind, placebo-controlled, cross-over study examined the effect of 6 days of supplementation: The purpose was to determine if 6 days of supplementation with A-GPC would augment isometric force production compared to a placebo. Thirteen college-aged males gave written informed consent to participate. The study was a double-blind, placebo-controlled, crossover design. It has been shown to increase lower body force production after 6 days of supplementation.

As Alpha-GPC seemed to be beneficial for certain physical and mental performance tasks, future research should focus on dosage, timing of consumption before testing measurement, bioavailability, longer-term supplementation, and subject selection, in order to reduce individual variability. The low-dose group (+8.5%), high-dose group (+7.5%), and caffeine (+2.0%) all showed improvements in vertical jump peak power in comparison to placebo.

One study using Alpha-GPC at 1,000 mg has reported that, in otherwise healthy men, an increase in plasma biomarkers of lipolysis (ketone bodies acetoacetate and 3-hydroxyacetate, as well as free fatty acids) was reported to occur 120 minutes after supplement ingestion.

Evidence strength: Preliminary to moderate for acute power output and growth hormone stimulation. Studies are largely small (n=7–20), often of short duration, and some use combination products. The available data are directionally consistent but insufficient to establish definitive efficacy. Further studies will be needed to confirm the results reported from these experiments.

4.6 Prevention of Dementia Conversion in Mild Cognitive Impairment

A nationwide population-based longitudinal study from South Korea examined real-world outcomes of alpha-GPC use in patients with MCI. This study longitudinally evaluated patients diagnosed with MCI between 2013 and 2016 to determine whether α-GPC use prevented conversion to dementia and increased stroke risk. This nationwide, population-based cohort study utilized data from the National Health Insurance Service (NHIS) database. In this study, α-GPC reduced the risk of stroke among the overall MCI population and in those whose MCI did not convert to AD dementia or VaD. There were no substantial differences in stroke risk for those whose MCI converted to AD dementia or VaD.

Evidence strength: Observational/retrospective cohort data. Subject to confounding; provides hypothesis-generating but not confirmatory evidence for dementia prevention.

4.7 Parkinson's Disease Cognitive Symptoms

In a separate open-label study, α-GPC demonstrated superior efficacy to piracetam in improving cognitive function in patients with Parkinson's disease.

Evidence strength: Very preliminary. Open-label design; independent replication required.

5. Body Systems and Health Areas Associated with GPC

• Central Nervous System: Acetylcholine synthesis and cholinergic neurotransmission; neuronal membrane phospholipid maintenance; hippocampal neurogenesis; neuroprotection in ischemic conditions.
• Cognitive Function: Memory formation, attention, learning, and executive function — particularly in the context of age-related decline and neurodegenerative disease.
• Neuromuscular System: Neuromuscular junction signaling via acetylcholine; potential augmentation of peak force and power output in athletes.
• Endocrine System: Growth hormone secretion through the action of acetylcholine-stimulated catecholamine release.
• Cardiovascular System: GPC has been expected to play a role in preventing brain disorders; however, recent studies have shown that intake of high levels of choline-containing compounds is related to trimethylamine N-oxide (TMAO) production in the liver, which is reportedly associated with the progression of atherosclerosis.
• Liver and Metabolic Organs: Choline is a critical component involved in the function of numerous organs including the liver, kidney, spleen, and lungs.
• Mood and Motivation: Dopaminergic and serotonergic modulation has been proposed in review literature as additional pathways through which cholinergic activity may influence affective states.

6. Dosage Forms and Dosages Reported in Studies

Commercial and Pharmaceutical Forms

L-alpha-GPC is available in two principal commercial forms: a viscous liquid GPC 85% and a powder (AlphaSize 100P). In Europe, it is sold in Italy and Poland as capsules or as a solution for injection at the maximum dose of 1000 mg. In dietary supplement markets it is most commonly encountered as oral capsules or tablets.

Dosages Used in Published Clinical Studies

• Alzheimer's disease and dementia: For Alzheimer's trials, patients have taken 400 mg three times per day (1,200 mg total).
• Amnestic MCI (12-week RCT): 100 subjects underwent double-blind soft capsule (600 mg αGPC) or placebo treatment for 12 weeks.
• Stroke/TIA multicenter trial: Alpha-GPC was administered after the attack at the daily dose of 1,000 mg intramuscularly for 28 days and orally at the dose of 400 mg three times daily during the following 5 months.
• Motivation study: Participants self-administered two capsules, once daily at bedtime for 2 weeks, for a total daily dose of 400 mg αGPC.
• Acute resistance exercise/GH study: 600 mg A-GPC administered 90 minutes prior to resistance exercise.
• Isometric strength study: 6 days of supplementation with A-GPC; 13 college-aged males participated in a double-blind, placebo-controlled, crossover design.
• Mood, cognition, and performance crossover study: Participants consumed 200 mg or 400 mg of Alpha-GPC in a randomized, double-blind, placebo-controlled, crossover design.
• Acute cognition study in healthy men: 20 resistance-trained males consumed either placebo, 630 mg A-GPC, or 315 mg A-GPC.
• Jump height/anaerobic performance: Subjects were given 300 mg of Alpha-GPC administered with a sports drink 1 hour before testing.
• General range reported in cognitive decline studies: For attenuating symptoms of cognitive decline, almost all studies used a dosage of 1,200 mg per day, divided into three doses of 400 mg. For boosting power output, studies have used a dosage of 300–600 mg, supplemented 30–60 minutes prior to exercise.

The FDA determined that intake of no more than 196.2 mg/person/day is considered generally recognized as safe (GRAS). For the European novel food application, L-alpha-GPC is proposed to be used in food supplements at a maximum use level of 203.7 mg/day, corresponding to 82.5 mg/day of choline. Note that these regulatory thresholds are significantly lower than the dosages used in clinical therapeutic trials, which typically range from 600–1,200 mg/day.

7. Safety Considerations and Interactions

General Tolerability

Alpha-GPC is generally well-tolerated, and animal models suggest that alpha-GPC has a low risk of toxicity. In humans, alpha-GPC has been used at a dosage of up to 1.2 grams (1,200 mg) daily for 6 months with no serious adverse effects reported. Human clinical studies have shown no adverse health effects of L-alpha-GPC or mild effects, and overall tolerability was stated to be good. The conclusion of safety is at the dose of 1,200 mg L-alpha-GPC per person per day.

In the large Italian multicenter trial (n=2,044): Adverse events were complained of by 44 patients (2.14%); in 14 (0.7%) the investigator preferred to discontinue therapy. The most frequent complaints were heartburn (0.7%), nausea-vomiting (0.5%), insomnia-excitation (0.4%), and headache (0.2%).

Toxicology

Previous clinical studies have shown that there are no serious side effects or toxicities when human subjects were orally administered αGPC (1,200 mg/day) for 6 months. In animal studies, LD50 values of αGPC in rodents and dogs were estimated at ≥10 and ≥3 g/kg respectively, by oral administration. Prolonged administration of αGPC (rodents: ≥1,000 mg/kg/day, dogs: ≥300 mg/kg/day) hardly showed serious adverse events for 26 weeks. In preclinical studies, results indicate that GPC is not genotoxic in vitro or in vivo. Extensive human studies indicate GPC causes no severe adverse effects. The no-observed-adverse-effect level (NOAEL) is 150 mg per kg of body weight per day.

Cardiovascular Risk: TMAO and Stroke Concerns

This is the most significant and actively evolving safety issue with alpha-GPC supplementation, particularly at higher doses. Alpha-GPC is generally well tolerated, but concerns have been raised about its potential association with increased cardiovascular disease risk due to its role in TMAO synthesis. A cohort study suggested that long-term use may be associated with a higher risk of stroke, although further research is needed to confirm these findings.

Choline, a metabolite of α-GPC, is an essential nutrient with potential adverse effects such as fishy body odor, vomiting, excessive sweating and salivation, hypotension, and liver diseases. However, a growing body of evidence suggests that a high plasma choline level is associated with a high risk of cardiovascular disease via trimethylamine-N-oxide (TMAO) produced by gut microbiota from choline. Some studies suggest that TMAO is associated with stroke as well as cardiovascular disease.

The critical epidemiological study on stroke risk: A 10-year cohort study including over 12 million human subjects (50 years or older) indicated that the use of Alpha-GPC was significantly associated with a 10-year incident stroke risk in a dose-responsive manner. Individuals using vs. not using α-GPC had a 46% higher risk of stroke. Researchers did note that while the development of stroke was associated with the duration of Alpha-GPC use, some of the individuals included in the cohort did have hypertension, which is a known comorbidity and contributing factor to cardiovascular disease.

However, another large population-based study arrived at a partially contradictory finding: In one nationwide longitudinal study, α-GPC reduced the risk of stroke among the overall MCI population and in those whose MCI did not convert to AD dementia or VaD. There were no substantial differences in stroke risk for those whose MCI converted to AD dementia or VaD. The authors of that study noted that while the efficacy of α-GPC may be limited in certain subgroups, there appears to be no reason to avoid α-GPC consumption solely to prevent stroke, based on their specific population.

Although alpha-GPC is largely considered to be safe due to its structural feature, multiple studies have indicated that a high plasma choline level is associated with an increased risk of cardiovascular disease through TMAO produced by gut microbiota from choline. A recent animal model study revealed that even though alpha-GPC supplements improved neurological functions, they increased the risk of atherosclerosis in hyperlipidemic rats. Possible risks of atherosclerosis and stroke await necessary validation.

The mechanistic basis involves gut microbiota conversion: This effect is linked to the metabolism of alpha-GPC into trimethylamine N-oxide (TMAO), a compound known to increase cardiovascular risk. Alpha-GPC also alters gut microbiota, increasing bacteria that produce TMAO and reducing beneficial bacteria, which may further contribute to cardiovascular risk. The TMAO–cardiovascular disease relationship is itself a subject of ongoing scientific debate; certain studies link increased TMAO to artery plaque, while opponents suggest that TMAO is a mere byproduct, not the instigator, of ailment.

An in vitro study on cardiac cells raised a separate consideration: long-term administration of GPC may exert cytotoxicity in a wide concentration range in cardiac myocytes. These results may draw attention to a comprehensive cardiac safety protocol for the testing of GPC. This finding awaits corroboration in vivo.

Regulatory Safety Thresholds

Although the US Food and Drug Administration (FDA) considers alpha-GPC as generally recognized as safe (GRAS) at dietary intake levels, many countries do not approve its use as a prescription drug, mostly due to the lack of robust evidence on efficacy and safety. Within the European Union, Alpha-GPC is classified as a novel food and is currently under review for authorization as an ingredient in food supplements, with an application submitted by Chemi S.p.A. in June 2023 for its use as a choline source at up to 203.7 mg per daily dose in capsules. Alpha-GPC is now under intense scrutiny in the EU. It has not received positive novel food authorization, and many member states have begun to classify it as an unauthorised ingredient for use in food supplements.

Interactions and Special Populations

According to the 2026 WADA List of Prohibited Substances, alpha-GPC is not prohibited for use in competitive sport. The combination with acetylcholinesterase inhibitors (such as donepezil) has been explored clinically and was the basis of the ASCOMALVA trial, showing a degree of additive effect; this combination should be regarded as pharmacodynamically interactive due to convergent cholinergic mechanisms. In light of the limited therapeutical results obtained in the past decades by the use of cholinesterase inhibitors in dementia, it is desirable to reconsider alpha-GPC in larger carefully controlled studies not only as monotherapy but also in association with cholinesterase inhibitor drugs.

References

• ScienceDirect Topics — Glycerophosphorylcholine overview
• Wikipedia — Glycerophosphorylcholine
• Li et al. (2025). L-Alpha-Glycerylphosphorylcholine: A Comprehensive Review of Its Preparation Techniques and Versatile Biological Effects. Journal of Food Science.
• PubMed — Unlocking the Potential of l-α-Glycerylphosphorylcholine: From Metabolic Pathways to Therapeutic Applications (2025)
• PubMed — Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men (2024)
• PubMed — Role of Gpcpd1 in intestinal alpha-glycerophosphocholine metabolism and TMAO production (2024)
• PMC — Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: systematic review and meta-analysis (2025)
• PubMed — Efficacy and safety of choline alphoscerate for amnestic mild cognitive impairment: a randomized double-blind placebo-controlled trial (2024)
• BMC Geriatrics — Efficacy and safety of choline alphoscerate for amnestic mild cognitive impairment (2024)
• PMC — Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis (2023)
• Journal of Alzheimer's Disease — Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: Systematic Review and Meta-Analysis (2023)
• PubMed — Revisiting choline alphoscerate profile: a new, perspective, role in dementia? (2013)
• Frontiers in Neurology — Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: systematic review and meta-analysis (2025)
• PMC — Association between L-α glycerylphosphorylcholine use and delayed dementia conversion: A nationwide longitudinal study in South Korea (2025)
• ScienceDirect — Association between L-α glycerylphosphorylcholine use and delayed dementia conversion (2025)
• PubMed — alpha-Glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial (1994)
• Frontiers in Cellular Neuroscience — Effects of choline containing phospholipids on the neurovascular unit: A review (2022)
• PMC — The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength (2015)
• Journal of the International Society of Sports Nutrition — Acute supplementation with alpha-glycerylphosphorylcholine augments growth hormone response to, and peak force production during, resistance exercise (2008)
• PMC — The effects of alpha-glycerylphosphorylcholine, caffeine or placebo on markers of mood, cognitive function, power, speed, and agility (2015)
• PMC — Alpha-Glycerylphosphorylcholine Increases Motivation in Healthy Volunteers: A Single-Blind, Randomized, Placebo-Controlled Human Study (2021)
• PMC — Association of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years (2021)
• Alzheimer's Drug Discovery Foundation — Alpha-GPC (choline alfoscerate) & Your Brain: Cognitive Vitality Rating
• Examine.com — Alpha-GPC: Benefits, Dosage, and Side Effects
• Examine.com — What are alpha-GPC's main drawbacks?
• PMC — Choline Alphoscerate: A Therapeutic Option for the Management of Subthreshold Depression in the Older Population (2025)
• EFSA Journal — Safety of L-alpha-glycerylphosphorylcholine (L-alpha-GPC) from soya phospholipids (lecithin) as a novel food pursuant to Regulation (EU) 2015/2283 (2026)
• European Commission — Novel food application on an L-alpha-GPC ingredient by Chemi S.p.A.
• PubMed — Absorption, tissue distribution and excretion of radiolabelled compounds in rats after administration of [14C]-L-alpha-glycerylphosphorylcholine (1993)
• PMC — Cloning of Glycerophosphocholine Acyltransferase (GPCAT) from Fungi and Plants (2016)
• News-Medical — Alpha-GPC: What Science Says About Its Role in Brain Health (2025)
• Molecular and Cellular Biochemistry — l-Alpha-glycerylphosphorylcholine can be cytoprotective or cytotoxic in neonatal rat cardiac myocytes (2019)